[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
August 18, 1999

Therapy for Fracture Prevention

Author Affiliations

Author Affiliation: Department of Medical Education, Providence Health System and Oregon Osteoporosis Center, Portland, Ore.

JAMA. 1999;282(7):687-689. doi:10.1001/jama.282.7.687

Nearly 60 years ago, Fuller Albright originally recognized postmenopausal osteoporosis in older women who presented with height loss, kyphosis, and back pain as a result of vertebral fractures.1 He astutely surmised that the waning of estrogen levels after menopause resulted in loss of bone tissue and increased skeletal fragility and predicted that estrogen therapy would prevent fractures. The relationship between cessation of ovarian function and loss of bone mass is now well established. An interval of relatively rapid bone loss occurs in the years immediately following menopause, and bone loss continues and even accelerates again in the very elderly. Estrogen therapy preserves bone mineral density (BMD) in both younger and older postmenopausal women.2 However, to date, no large randomized clinical trials have evaluated the antifracture efficacy of estrogen.

First Page Preview View Large
First page PDF preview
First page PDF preview